Indications
Treatment of severe osteoporosis in postmenopausal women at high risk for fracture to reduce the risk of vertebral and hip fractures. Treatment of severe osteoporosis in adult men at increased risk of fracture. The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks.
Composition
- Active substance
- strontium ranelate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Protelos
- Active substance
- strontium ranelate
- ATC code
- M05BX03
- Therapeutic area
- Osteoporosis, Postmenopausal
- Marketing authorisation holder
- Les Laboratoires Servier